The Effect of Rosiglitazone on Glycemia and ?-Cell Function in Type 2 Diabetic Patients
- VernacularTitle:罗格列酮对2型糖尿病的降糖效果和胰岛?细胞功能变化观察
- Author:
Minxiang LEI
;
Jing WU
;
Huiling CHEN
;
Al ET
- Publication Type:Journal Article
- Keywords:
Type 2 diabetes;
Insulin resistance;
Rosiglitazone;
?-cell function
- From:
Journal of Chinese Physician
2000;0(12):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of rosiglitazone (RSG) on glycemia and ?-cell function in type 2 diabetic patients. Mothods Open-label and self-match trial was carried out. 31 cases of type 2 diabetic patients were divided into RSG monotherapy group (n=13), RSG plus metformin group (n=9), and RSG plus sulphonylureas group. All the patients received treatment for 12 weeks. Weight, body mass index, FBG, FINS, blood pressure, TG, Tch, HDL, LDL, ALT, AST and TBIL were determined before and after therapy. The insulin resistance (HOMA-IR) and ?-cell function (HOMA-?) of the patients were evaluated using homeostasis model assessment (HOMA). Results Compared with before treatment, there was a significant improvement in FBG, FINS, HOMA-? and HOMA-IR in all the patients after treatment (FBG 8.89?2.49mmol/L, FINS 17.89?5.78mU/L, HOMA-? 79.75?41.28,HOMA-IR 7.15?3.40 vs FBG 7.27?2.26mmol/L, FINS 14.33?3.82mU/L,HOMA-? 120.84?140.66,HOMA-IR 4.63?1.81, respectively,P
